Highlights

  • Cambium Bio targets first-patient enrolment by year-end, subject to final contractor agreements, clinical batch release and shareholder approval.
  • The company plans its first clinical batch in November, with release testing and engineering-batch comparability still required before use.
  • Shareholders will consider a A$7.1 million placement on 9 November, with the conditional offer lapsing without approval by November-end.
  • Cambium held A$1.194 million at quarter-end and expects spending to increase once the planned pivotal trial begins enrolling patients.

Three unfinished steps sit between Cambium Bio (ASX:CMB) and its target of enrolling the first Elate Ocular Phase 3 patient by the end of 2026. A contractor agreement, clinical batch release and shareholder approval of funding remain open. The September quarterly report records progress into Phase 3 manufacturing, alongside A$1.194 million in closing cash.

Manufacturing and Contracting Set the Pace

The selected contract research organisation’s master services agreement had not been signed. The contracting target has moved from the third quarter to the fourth quarter of 2026.

An engineering batch began manufacture on 19 October. The first clinical batch is scheduled for November and must pass release testing and demonstrate comparability with that engineering batch.

This is the first Phase 3-scale run of the three-step pathogen inactivation process. Cambium identifies biological manufacturing risk, with a full viral clearance report for the final UV-C device still to be submitted and FDA acceptance pending.

Updated trial protocol and statistical analysis documents were received by the FDA’s biologics centre on 14 September. Ethics approvals from Bellberry in Australia and Advarra in the United States are in place.

Placement Approval Precedes Higher Spending

The annual general meeting on 9 November will consider a A$7.1 million placement. The proposal comprises 14,791,667 shares at A$0.48 to four investors, including ZYBT, and lapses without approval by 30 November.

Quarterly net operating cash outflow was A$735,000, including approximately A$506,000 of research and development. Royalties from a separate product generated A$146,000 in receipts, and a July placement raised A$1.008 million before costs.

Cambium’s stated 6.73-quarter funding estimate includes a A$3.75 million undrawn RDTI pre-financing facility and excludes the proposed placement. The facility charges 16% annual interest compounded daily, requires minimum cash of A$300,000 and an equity raise of at least A$4 million after the AGM.

The company expects burn to increase when the trial begins. It says research spending can be phased to match available funds.

Regulatory Path Remains a Set of Targets

Elate Ocular retains Fast Track and Orphan Drug designations for dry eye disease secondary to chronic graft-versus-host disease. The FDA has agreed that one pivotal study plus confirmatory evidence can be considered, with that additional evidence to be discussed after topline data.

Cambium targets enrolment completion in mid-2027 and topline results in the fourth quarter of 2027. A rolling biologics licence application is targeted for mid-2028, followed by potential approval in late 2028 or early 2029.

These dates depend on manufacturing, contracting, funding, trial outcomes and regulatory review. Partnering discussions have occurred, but no licensing terms have been agreed. Management intends to consider an out-licensing process after Phase 3 begins.